{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:37:20Z","timestamp":1762522640665,"version":"build-2065373602"},"reference-count":106,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfeicoamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The COVID-19 pandemic represents a milestone in vaccine research and development in a global context. A worldwide effort, as never seen before, involved scientists from all over the world in favor of the fast, accurate and precise construction and testing of immunogens against the new coronavirus, SARS-CoV-2. Among all the vaccine strategies put into play for study and validation, those based on recombinant viral vectors gained special attention due to their effectiveness, ease of production and the amplitude of the triggered immune responses. Some of these new vaccines have already been approved for emergency\/full use, while others are still in pre- and clinical trials. In this article we will highlight what is behind adeno-associated vectors, such as those presented by the immunogens ChaAdOx1, Sputnik, Convidecia (CanSino, Tianjin, China), and Janssen (Johnson &amp; Johnson, New Jersey, EUA), in addition to other promising platforms such as Vaccinia virus MVA, influenza virus, and measles virus, among others.<\/jats:p>","DOI":"10.3390\/vaccines9101101","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T21:39:29Z","timestamp":1632865169000},"page":"1101","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis"],"prefix":"10.3390","volume":"9","author":[{"given":"Danielle Soares de Oliveira","family":"Daian e Silva","sequence":"first","affiliation":[{"name":"Laborat\u00f3rio de Virologia B\u00e1sica e Aplicada, Departamento de Microbiologia, Instituto de Ci\u00eancias Biol\u00f3gicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1vio Guimar\u00e3es","family":"da Fonseca","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Virologia B\u00e1sica e Aplicada, Departamento de Microbiologia, Instituto de Ci\u00eancias Biol\u00f3gicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil"},{"name":"CT Vacinas, BH-TEC Instituto de Ci\u00eancias Biol\u00f3gicas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021, August 26). WHO Director-General\u2019s Opening Remarks at the Media Briefing on COVID-19. Available online: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"World Health Organization (2021, August 26). Draft Landscape of COVID-19 Candidate Vaccines. Available online: https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjz15f24Nv8bTLuc4wf7gnsqQshmLJxEHFNcQ&url=https%3A%2F%2Fwww.who.int%2Fdocs%2Fdefault-source%2Fa-future-for-children%2Fnovel-coronavirus_landscape_covid-19.pdf%3Fsfvrsn%3D4d8bd201_1&usg=AOvVaw0YA9eJeQBREZem2QfAVpOc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2217\/fvl.13.129","article-title":"Modified vaccinia virus Ankara as vaccine vectors in human and veterinary medicine","volume":"9","author":"Quinan","year":"2014","journal-title":"Future Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.vaccine.2008.11.094","article-title":"A prime\/boost DNA\/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis","volume":"27","author":"Carson","year":"2009","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.vaccine.2013.05.039","article-title":"Protection against H7N3 high pathogenicity avian influenza in chickens immunized with a recombinant fowlpox and an inactivated avian influenza vaccines","volume":"31","author":"Bertran","year":"2013","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4161\/hv.21080","article-title":"A vaccinia virus renaissance\u2014New vaccine and immunotherapeutic uses after smallpox eradication","volume":"8","author":"Verardi","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjp.2008.349","article-title":"Viral vectors: From virology to transgene expression","volume":"157","author":"Bouard","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2020). Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses, 12.","DOI":"10.3390\/v12111324"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0262-4079(20)31303-8","article-title":"Inside the race for a vaccine","volume":"247","author":"Gilbert","year":"2020","journal-title":"New Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: From immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in Viral Vector-Based Vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/cgt.2009.17","article-title":"Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity","volume":"16","author":"Osada","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: Where we stand and challenges ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform","volume":"11","author":"Chiuppesi","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/jmv.26769","article-title":"SARS-CoV-2 nucleocapsid protein intranasal inoculation induces local and systemic T cell responses in mice","volume":"93","author":"He","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_19","first-page":"ji2100421","article-title":"Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity","volume":"30","author":"Matchett","year":"2021","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New Vaccine Technologies to Combat Outbreak Situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.coviro.2020.07.012","article-title":"Harnessing virus tropism for dendritic cells for vaccine design","volume":"44","author":"Mosaheb","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1021\/mp060098+","article-title":"Vaccine Delivery Methods Using Viral Vectors","volume":"4","author":"Ljungberg","year":"2007","journal-title":"Mol. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2144\/97236st07","article-title":"Compact, Synthetic, Vaccinia Virus Early\/Late Promoter for Protein Expression","volume":"23","author":"Chakrabarti","year":"1997","journal-title":"BioTechniques"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/21645515.2018.1513439","article-title":"Poxviral promoters for improving the immunogenicity of MVA delivered vaccines","volume":"15","author":"Alharbi","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2005.08.101","article-title":"Development of nonhuman adenoviruses as vaccine vectors","volume":"24","author":"Bangari","year":"2006","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0300-483X(02)00055-0","article-title":"Non-clinical vaccine safety assessment","volume":"174","author":"Verdier","year":"2002","journal-title":"Toxicology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1038\/sj.gt.3302624","article-title":"Downstream processing of viral vectors and vaccines","volume":"12","author":"Morenweiser","year":"2005","journal-title":"Gene Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"107608","DOI":"10.1016\/j.biotechadv.2020.107608","article-title":"Vero cell upstream bioprocess development for the production of viral vectors and vaccines","volume":"44","author":"Kiesslich","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/cei.13295","article-title":"Emerging viruses and current strategies for vaccine intervention","volume":"196","author":"Afrough","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: Deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41551-020-00658-w","article-title":"Development of vaccines and antivirals for combating viral pandemics","volume":"4","author":"Pardi","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"Lambe","year":"2020","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Dicks, M., Spencer, A., Edwards, N., Wadell, G., Bojang, K., Gilbert, S., Hill, A.V.S., and Cottingham, M.G. (2012). A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040385"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"eaba8399","DOI":"10.1126\/sciadv.aba8399","article-title":"A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques","volume":"6","author":"Haddock","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_36","unstructured":"Astrazeneca Media Center (2021, August 26). AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy. March 2021. Available online: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html#!."},{"key":"ref_37","unstructured":"U.S. National Institutes of Health (2021, August 28). ClinicalTrials.gov. Official Title: Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults. ClinicalTrials.gov Identifier: NCT04516746, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04516746."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(21)01699-8","article-title":"Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: A substudy of two randomised controlled trials (COV001 and COV002)","volume":"398","author":"Flaxman","year":"2021","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"20","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"ref_40","unstructured":"U.S. National Institutes of Health (2021, August 28). ClinicalTrials.gov. Official Title: Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 (RESIST). ClinicalTrials.gov Identifier: NCT04530396, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04530396."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/d41586-021-01813-2","article-title":"Mounting evidence suggests Sputnik COVID vaccine is safe and effective","volume":"595","author":"Nogrady","year":"2021","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/d41586-021-00315-5","article-title":"Could mixing COVID vaccines boost immune response?","volume":"590","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"ref_43","unstructured":"Gamaleya National Research Centre for Epidemiology and Microbiology (2021, August 26). Sputnik V Demonstrates 97.6% Efficacy According to Analysis of Data from 3.8 Million Vaccinated Persons in Russia Making it the Most Efficient COVID-19 Vaccine in the World. Available online: https:\/\/sputnikvaccine.com\/newsroom\/pressreleases\/sputnik-v-demonstrates-97-6-efficacy-according-to-the-analysis-of-data-of-3-8-million-vaccinated-per\/."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Rossi, A.H., Ojeda, D.S., Varese, A., Sanchez, L., Ledesma, M.M.G.L., Mazzitelli, I., Juli\u00e1, A.A., Rouco, S.O., Pallar\u00e9s, H.M., and Navarro, G.S.C. (2021). Sputnik V Vaccine Elicits Seroconversion and Neutralizing Capacity to SARS CoV-2 after a Single Dose. Cell Rep. Med.","DOI":"10.1016\/j.xcrm.2021.100359"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Claro, F., Silva, D., Rodriguez, M., Rangel, R., and de Waard, J.H. (2021). IgG Antibody response to the Sputnik V vaccine: Previous SARS-CoV-2 seropositive individuals might need just one vaccine dose. Int. J. Infect. Dis., 31.","DOI":"10.1016\/j.ijid.2021.07.070"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gushchin, V., Dolzhikova, I., Shchetinin, A., Odintsova, A., Siniavin, A., Nikiforova, M., Pochtovyi, A., Shidlovskaya, E., Kuznetsova, N., and Burgasova, O. (2021). Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines, 9.","DOI":"10.3390\/vaccines9070779"},{"key":"ref_47","unstructured":"U.S. National Institutes of Health (2021, August 28). ClinicalTrials.gov. Official Title: An Open Study on the Safety, Tolerability, and Immunogenicity of \u201cSputnik Light\u201d Vaccine. ClinicalTrials.gov Identifier: NCT04713488, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04713488."},{"key":"ref_48","unstructured":"Gamaleya National Research Centre for Epidemiology and Microbiology (2021, August 26). General Information. Available online: https:\/\/sputnikvaccine.com\/about-vaccine\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"10","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"npj Vaccines"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","unstructured":"U.S. National Institutes of Health (2021, August 28). ClinicalTrials.gov. Official Title: A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE). ClinicalTrials.gov Identifier: NCT04505722, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04505722."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMc2108829","article-title":"Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination","volume":"385","author":"Barouch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_55","unstructured":"Johnson & Johnson (2021, August 26). Johnson & Johnson COVID-19 Vaccine Booster, After Single Dose Primary Regimen, Provided Rapid and Robust Increase in Spike-binding Antibodies. Available online: https:\/\/www.jnj.com\/johnson-johnson-announces-data-to-support-boosting-its-single-shot-covid-19-vaccine."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_57","unstructured":"U.S. National Institutes of Health (2021, August 08). ClinicalTrials.gov. Official Title: A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV). ClinicalTrials.gov Identifier: NCT04341389, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04341389."},{"key":"ref_58","unstructured":"U.S. National Institutes of Health (2021, August 28). ClinicalTrials.gov. Official Title: Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above. ClinicalTrials.gov Identifier: NCT04526990, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04526990."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0147-9571(03)00025-0","article-title":"Smallpox vaccination and bioterrorism with pox viruses","volume":"26","author":"Mayr","year":"2003","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","article-title":"ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice","volume":"35","author":"Alharbi","year":"2017","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e2026207118","DOI":"10.1073\/pnas.2026207118","article-title":"Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination","volume":"118","author":"Tscherne","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","unstructured":"U.S. National Institutes of Health (2021, August 28). ClinicalTrials.gov. Official Title: Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19. ClinicalTrials.gov Identifier: NCT04569383, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04569383."},{"key":"ref_63","unstructured":"U.S. National Institutes of Health (2021, August 28). ClinicalTrials.gov. Official Title: Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 (MVA-SARS-2-ST). ClinicalTrials.gov Identifier: NCT04895449, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04895449."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arriaza, J., Garaigorta, U., P\u00e9rez, P., L\u00e1zaro-Fr\u00edas, A., Zamora, C., Gastaminza, P., del Fresno, C., Casasnovas, J.M., Sorzano, C.S., and Sancho, D. (2021). COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice. J. Virol., 95.","DOI":"10.1128\/JVI.02260-20"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arriaza, J., Arn\u00e1ez, P., Gomez, C.E., Sorzano, C.O.S., and Esteban, M. (2013). Improving Adaptive and Memory Immune Responses of an HIV\/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066894"},{"key":"ref_66","unstructured":"U.S. National Institutes of Health (2021, August 28). ClinicalTrials.gov. Official Title: A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19. ClinicalTrials.gov Identifier: NCT04639466, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04639466."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/biol.1995.0028","article-title":"Influenza virus vectors","volume":"23","author":"Palese","year":"1995","journal-title":"Biologicals"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Loes, A.N., Gentles, L.E., Greaney, A.J., Crawford, K.H.D., and Bloom, J.D. (2020). Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice. Viruses, 12.","DOI":"10.1101\/2020.08.12.248823"},{"key":"ref_69","unstructured":"U.S. National Institutes of Health (2021, August 21). ClinicalTrials.gov. Official Title: A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19. ClinicalTrials.gov Identifier: NCT04809389, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04809389."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e02180-19","DOI":"10.1128\/mBio.02180-19","article-title":"Generation of DelNS1 Influenza Viruses: A Strategy for Optimizing Live Attenuated Influenza Vaccines","volume":"10","author":"Wang","year":"2019","journal-title":"mBio"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1086\/649428","article-title":"A Novel Type of Influenza Vaccine: Safety and Immunogenicity of Replication-Deficient Influenza Virus Created by Deletion of the Interferon Antagonist NS1","volume":"201","author":"Wacheck","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Vora, L.K., Pandya, A.K., and Patravale, V.B. (2021). Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discov. Today.","DOI":"10.1016\/j.drudis.2021.07.021"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.micinf.2018.01.005","article-title":"Measles-derived vaccines to prevent emerging viral diseases","volume":"20","author":"Frantz","year":"2018","journal-title":"Microbes Infect."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.virol.2014.01.002","article-title":"Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein","volume":"452\u2013453","author":"Escriou","year":"2014","journal-title":"Virology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"11654","DOI":"10.1128\/JVI.01815-15","article-title":"A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform","volume":"89","author":"Malczyk","year":"2015","journal-title":"J. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Lu, M., Dravid, P., Zhang, Y., Trivedi, S., Li, A., Harder, O., Kc, M., Chaiwatpongsakorn, S., Zani, A., and Kenney, A. (2021). A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc. Natl. Acad. Sci., 118.","DOI":"10.1073\/pnas.2026153118"},{"key":"ref_77","first-page":"1","article-title":"A single dose of recombinant VSV-\u2206G-spike vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Tamir","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/d41586-019-03490-8","article-title":"Make Ebola a thing of the past: First vaccine against deadly virus approved","volume":"575","author":"Callaway","year":"2019","journal-title":"Nature"},{"key":"ref_79","unstructured":"U.S. National Institutes of Health (2021, August 21). ClinicalTrials.gov. Official Title: Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine. ClinicalTrials.gov Identifier: NCT04608305, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04608305."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.chom.2020.12.010","article-title":"Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models","volume":"29","author":"Ku","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_82","unstructured":"U.S. National Institutes of Health (2021, August 21). ClinicalTrials.gov. Official Title: Immunity and Safety of Covid-19 Synthetic Minigene Vaccine. ClinicalTrials.gov Identifier: NCT04276896, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04276896."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Ko, E.-J., and Robert-Guroff, M. (2019). Dendritic Cells in HIV\/SIV Prophylactic and Therapeutic Vaccination. Viruses, 12.","DOI":"10.3390\/v12010024"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","year":"2020","journal-title":"Nat. Mater."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1128\/JVI.03244-14","article-title":"Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways","volume":"89","author":"Thiele","year":"2015","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/JVI.02055-12","article-title":"Comparative Analysis of Simian Immunodeficiency Virus Gag-Specific Effector and Memory CD8 + T Cells Induced by Different Adenovirus Vectors","volume":"87","author":"Tan","year":"2013","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/viro.2000.0792","article-title":"A Striking Property of Recombinant Poxviruses: Efficient Inducers of in Vivo Expansion of Primed CD8+ T Cells","volume":"280","author":"Zavala","year":"2001","journal-title":"Virology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): A randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/mic.0.049601-0","article-title":"Pre-existing immunity against vaccine vectors\u2014Friend or foe?","volume":"159","author":"Saxena","year":"2013","journal-title":"Microbiology"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Pettini, E., Pastore, G., Fiorino, F., Medaglini, D., and Ciabattini, A. (2021). Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity?. Vaccines, 9.","DOI":"10.3390\/vaccines9030289"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.vaccine.2017.02.032","article-title":"Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial","volume":"35","author":"Jackson","year":"2017","journal-title":"Vaccine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.immuni.2010.10.008","article-title":"From Vaccines to Memory and Back","volume":"33","author":"Sallusto","year":"2010","journal-title":"Immunity"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-020-00240-0","article-title":"Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans","volume":"5","author":"Capone","year":"2020","journal-title":"npj Vaccines"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/d41586-021-00998-w","article-title":"COVID vaccines and blood clots: Five key questions","volume":"592","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/d41586-021-00940-0","article-title":"How could a COVID vaccine cause blood clots? Scientists race to investigate","volume":"592","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"384","author":"Skowronski","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_101","unstructured":"U.S. National Institutes of Health (2021, August 28). ClinicalTrials.gov. Official Title: Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults. ClinicalTrials.gov Identifier: NCT04798001, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04798001."},{"key":"ref_102","unstructured":"U.S. National Institutes of Health (2021, August 28). ClinicalTrials.gov. Official Title: Study of a Live rNDV Based Vaccine Against COVID-19. ClinicalTrials.gov Identifier: NCT04871737, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04871737."},{"key":"ref_103","unstructured":"U.S. National Institutes of Health (2021, August 28). ClinicalTrials.gov. Official Title: Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand. ClinicalTrials.gov Identifier: NCT04764422, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04764422."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Sun, W., Liu, Y., Amanat, F., Gonz\u00e1lez-Dom\u00ednguez, I., McCroskery, S., Slamanig, S., Coughlan, L., Rosado, V., Lemus, N., and Jangra, S. (2021). A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters. bioRxiv, Available online: https:\/\/www.biorxiv.org\/content\/10.1101\/2021.07.06.451301v1.","DOI":"10.1038\/s41467-021-26499-y"},{"key":"ref_105","unstructured":"U.S. National Institutes of Health (2021, August 28). ClinicalTrials.gov. Official Title: Phase 1 Intranasal Parainfluenza Virus Type 5-SARS CoV-2 S Vaccine in Healthy Adults (CVXGA1-001). ClinicalTrials.gov Identifier: NCT04954287, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04954287."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"eabi5246","DOI":"10.1126\/sciadv.abi5246","article-title":"Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5\u2013based COVID-19 vaccine","volume":"7","author":"An","year":"2021","journal-title":"Sci. Adv."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/10\/1101\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:06:59Z","timestamp":1760166419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/10\/1101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":106,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["vaccines9101101"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9101101","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2021,9,29]]}}}